REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS FOR RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) AND MONOCLONAL ANTIBODIES (MAB) THERAPIES

被引：0
|
作者：
Feng, C. [1 ]
Murphy, L. [2 ]
Engel-Nitz, N. [2 ]
Nguyen, A. [2 ]
Patel, A. [1 ]
DuCharme, M. [2 ]
Fu, C. [1 ]
Shah, G. [3 ]
机构：
[1] Kite Pharma, Santa Monica, CA USA
[2] Optum, Eden Prairie, MN USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD178
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [21] Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine
    Hamadani, Mehdi
    Lucero, Melanie
    Devos, Jakob D.
    Chen, Lei
    EJHAEM, 2024, 5 (05): : 1110 - 1113
  • [22] Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)
    Dahiya, Saurabh
    Spiegel, Jay Y.
    Lee, Dasom
    Mohammed, Turab
    Lutfi, Forat
    Goyal, Anmol
    Hana, Caroline
    Chavez, Julio C.
    Ionescu, Filip
    Frank, Matthew J.
    Bharadwaj, Sushma
    Sandoval-Sus, Jose
    Beitinjaneh, Amer M.
    Lekakis, Lazaros J.
    McGuirk, Joseph P.
    Locke, Frederick L.
    Miklos, David B.
    Jain, Michael D.
    BLOOD, 2023, 142
  • [23] Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma
    Dharmani, Charles
    Unni, Sudhir
    Pham, Ngan
    Shaikh, Nazneen Fatima
    Xiong, Yan
    Vashi, Rohan
    Fofah, Oluwatosin
    Strubing, Alessandria
    Salas, Maribel
    Tu, Nora
    Wooddell, Margaret
    Zhou, Xiaoyu
    Near, Aimee
    FUTURE ONCOLOGY, 2024, 20 (15) : 1013 - 1030
  • [24] Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma
    Chihara, Dai
    Liao, Laura
    Tkacz, Joseph
    Franco, Anjali
    Lewing, Benjamin
    Kilgore, Karl M.
    Nastoupil, Loretta J.
    Chen, Lei
    BLOOD, 2023, 142 (12) : 1047 - 1055
  • [25] COMPLETENESS OF REAL-WORLD DATA (RWD) IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN UNITED STATES (US) COMMUNITY ONCOLOGY/HEMATOLOGY PRACTICES (CH/OS)
    Feinberg, B.
    Klink, A.
    Balanean, M. P. H. A.
    Schuler, T.
    McAllister, L.
    Liassou, D.
    Gajra, A.
    Porter, D.
    VALUE IN HEALTH, 2022, 25 (07) : S304 - S304
  • [26] Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
    Iqbal, Madiha
    Khurana, Arushi
    Chavez, Julio
    Rosenthal, Allison C.
    Li, Zhuo
    Craver, Emily
    Aditi, Saha
    Epperla, Narendranath
    Annunzio, Kaitlin
    Awan, Farrukh T.
    Isufi, Iris
    Dholaria, Bhagirathbhai
    Bhaskar, Shakthi
    Maakaron, Joseph
    Sumransub, Nuttavut
    Fijalka, Andrew
    Sandoval-Sus, Jose
    Ivanov, Stanislav
    Lin, Yi
    Kharfan-Dabaja, Mohamed A.
    BLOOD, 2022, 140 : 10396 - 10398
  • [27] Assessing risk of bias in comparative effectiveness studies of chimeric antigen receptor T-cell therapies for relapsed or refractory large B-cell lymphoma
    Munoz, Javier
    Sun, Fang
    Bian, John
    Smith, Nancy
    Dieyi, Christopher
    Zhang, Jie
    Song, Qinghua
    Xu, Hairong
    Carson, Kenneth
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 307 - 307
  • [28] Healthcare Resource Utilization and Costs in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A US Real-World Observational Study
    Yang, Xiaoqin
    Laliberte, Francois
    Germain, Guillaume
    Raut, Monika
    Duh, Mei Sheng
    Sen, Shuvayu S.
    Lejeune, Dominique
    Desai, Kaushal D.
    Armand, Philippe
    BLOOD, 2019, 134
  • [29] Cost and Healthcare Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Medicare Beneficiaries Receiving Chimeric Antigen Receptor T-Cell Vs. Autologous and Allogeneic Hematopoietic Cell Transplants
    Mohammadi, Iman
    Purdum, Anna G.
    Wong, Anny C.
    Schroeder, Amy
    Kilgore, Karl M.
    Shah, Gunjan L.
    BLOOD, 2020, 136
  • [30] Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
    Nastoupil, Loretta J.
    Andersen, Clark
    Ayers, Amy
    Wang, Yucai
    Habermann, Thomas M.
    Chihara, Dai
    Kahl, Brad S.
    Link, Brian K.
    Ayyappan, Sabarish
    Cohen, Jonathon B.
    Martin, Peter
    Lossos, Izidore S.
    Casulo, Carla
    Lin, Ruitao
    Li, Ziyi
    Larson, Melissa A.
    Maurer, Matthew J.
    Huynh, Lynn
    Gao, Chi
    Ramasubramanian, Ramya
    Duh, Mei Sheng
    Mutebi, Alex
    Wang, Tongsheng
    Jun, Monika
    Wang, Anthony
    Kamalakar, Rajesh
    Kalsekar, Anupama
    Cerhan, James R.
    Flowers, Christopher R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S442 - S443
12345